脂蛋白与抗血小板药物对CABG术后1年静脉桥血管通畅性的影响
本研究为DACAB试验的事后分析,探讨基线LDL-C水平对CABG术后1年静脉桥血管通畅性的影响。结果显示基线LDL-C与1年桥血管通畅性无关,而替格瑞洛联合阿司匹林较单用阿司匹林更能维持桥血管通畅,提示早期静脉桥病变主要机制可能为血栓而非动脉粥样硬化。
要点
- 基线LDL-C水平与CABG术后1年静脉桥血管通畅性无显著关联。
- 无论基线LDL-C水平如何,替格瑞洛联合阿司匹林均优于单用阿司匹林维持桥血管通畅。
- 早期静脉桥病变的主要机制可能为血栓而非动脉粥样硬化。
核心结论
- 基线LDL-C与CABG术后1年静脉桥血管通畅性无关。
- 无论基线LDL-C水平,替格瑞洛联合阿司匹林优于单用阿司匹林维持桥血管通畅。
- 早期静脉桥病变的主要因素可能为血栓而非动脉粥样硬化。
研究设计与样本
- DACAB试验的事后分析,随机对照试验比较替格瑞洛联合阿司匹林或替格瑞洛与阿司匹林。
- 研究对象为中国行CABG的患者,按基线LDL-C分层:低LDL组148例430条静脉桥,高LDL组352例1030条静脉桥。
- 主要结局为1年静脉桥血管通畅(Fitzgibbon A级),通过冠状动脉CT血管成像或冠状动脉造影评估。
主要发现
- 低LDL组基线/1年LDL-C为1.4/1.6 mmol/L,高LDL组为2.6/2.4 mmol/L。
临床怎么用
- CABG术后无论基线LDL-C水平,可考虑替格瑞洛联合阿司匹林以改善1年静脉桥血管通畅。
- 基线LDL-C水平不宜作为预测1年静脉桥血管通畅性的指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: It remains unclear whether aggressive low-density lipoprotein cholesterol (LDL-C) management (<1.8 mmol/L) can slow the process of vein graft stenosis. This study aimed to explore the impact of baseline LDL-C levels on vein graft patency in patients on ticagrelor with or without aspirin 1 year after coronary artery bypass grafting (CABG). METHODS: This was a post hoc analysis of the DACAB (Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery) trial (NCT02201771), a randomized controlled trial (ticagrelor + aspirin or ticagrelor vs aspirin) of patients undergoing CABG in China. The study subjects were stratified as LDL-low (baseline LDL-C <1.8 mmol/L, 148 patients with 430 vein grafts) versus LDL-high (baseline LDL-C ≥1.8 mmol/L, 352 patients with 1030 vein grafts). The primary outcome was the 1-year vein graft patency (Fitzgibbon grade A) assessed by coronary computed tomographic angiography or coronary angiography. RESULTS: Baseline/1-year LDL-C were 1.4/1.6 and 2.6/2.4 mmol/L in the LDL-low and LDL-high subgroups, respectively. Regardless of antiplatelet regimen, no significant inter-subgroup difference was observed for 1-year graft patency (LDL-low: 83.8% [359/430 grafts]; LDL-high: 82.3% [848/1030 grafts]; adjusted OR for non-patency [ORadj], 0.96; 95% confidence interval [CI], 0.62-1.50, P = .857). For both subgroups, the 1-year graft patency rates were greater with ticagrelor + aspirin versus aspirin (LDL-low: ORadj, 0.41; 95% CI, 0.17-0.97; LDL-high: ORadj, 0.38; 95% CI, 0.20-0.71; inter P = .679). CONCLUSIONS: In general, baseline LDL-C is not associated with 1-year vein graft patency after CABG. Regardless of the baseline LDL-C levels, ticagrelor + aspirin was superior to aspirin alone in maintaining vein graft patency. The primary factor causing early vein graft disease might not be atherosclerosis but thrombosis.
引用
- Zhu J, Zhu Y, Zhang M, et al. Influence of lipoproteins and antiplatelet agents on vein graft patency 1 year after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2020. PMID: 32359899. doi:10.1016/j.jtcvs.2020.03.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。